Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (14187)	11/17/2004 5:17:47 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 52153

biz.yahoo.com Interesting announcement from NABI this afternoon. Especially as to why they couldn't make any inferences from Phase II test. Would like to think they have a viable drug for this condition, but seems they are several years away from any definite answers.

To: zeta1961 who wrote (14187)	11/17/2004 5:59:40 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

A couple of comments on DSCO: First, they showed significantly reduced mortality vs. both Exosurf and Survanta at Day 14 in their RDS trial. P<.0001 vs Exosurf, P not disclosed vs Survanta, but I'm sure it was lower given that there were fewer Survanta patients (it was a 2:2:1 randomization). Deaths were 25/427 (4.7%) vs. 49/509 (9.6%) vs. 27/258 (10.5%) for Surfaxin, Exosurf and Survanta respectively. Note the trial was halted early because of the good results. They show a Kaplan-Meier curve where the divergence becomes even more striking as you go further out to about 20 days. At 2 months, Surfaxin has a 81% survival, with (somewhat surprisingly) Exosurf next with about a 77% survival and Survanta last with about a 74% rate (all eyeballed from graph). The curves stay flat from there. Finally, the ARDS trial in the NEJM was with a surfactant that is different in composition from DSCO's and with a dosage that DSCO clearly believes was inadequate. Peter